Skip to main content
Premium Trial:

Request an Annual Quote

AB Sciex Acquires Eksigent's LC Business

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AB Sciex has acquired the liquid chromatography business of Eksigent Technologies for an undisclosed amount, the firm said today.

The acquired technologies complement AB Sciex's mass spectrometry business and provide the firm with an entry into the LC market. Among the acquired products are Eksigent's NanoLC-Ultra System for proteomics, the cHiPLC-nanoflex System for protein peptide separations, and the ExpressHT-Ultra HPLC System for LC/MS studies of pharmacokinetics and drug metabolism.

In addition to the acquired technologies, AB Sciex gains approximately 50 employees in Eksigent's R&D, manufacturing, and sales operations, located in Dublin, Calif.

"Eksigent's portfolio of HPLC technologies is among the most innovative within the industry and is extremely complementary to our market-leading mass spectrometry systems," AB Sciex President Andy Boorn, said in a statement. "We expect to further develop and broaden the use of these technologies for a variety of life science applications."

AB Sciex is a subsidiary of Danaher, following that firm's recent purchase of MDS Analytical Technologies — including the mass spec joint venture with Life Technologies — for $1.1 billion.

Boorn was named a president of the firm along with Laura Lauman, formerly the head of mass spec for Life Technologies. Following its recent launch as AB Sciex, Lauman said during a conference call that the new corporate structure "enables us to make strategic investments and partnerships as well as identify and acquire emerging technologies that are complementary to our business."

"Danaher is a large company that's known for expanding its portfolio, and that is something we'll consider as well," she added.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.